Drug Profile
A 200 - AfaSci
Alternative Names: A-200Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator AfaSci
- Class Analgesics; Small molecules
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Neuropathic pain
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 22 Jul 2016 A 200 - AfaSci is available for licensing as of 22 Jul 2016. http://www.afasci.com/index.php/
- 22 Jul 2016 Preclinical trials in Neuropathic pain in USA (unspecified route)